Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rita Volkinshtein

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
BMC Bioinformatics|May 10, 2015
Is this the right normalization? A diagnostic tool for ChIP-seq normalizationClaudia Angelini, Ruth Heller, Rita Volkinshtein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosisGiancarlo Comi, Yuval Dadon, Nissim Sasson, et al.
The Lancet. Neurology|January 27, 2024
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyRalf Reilmann, Karen E Anderson, Andrew Feigin, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
BMC Bioinformatics|May 10, 2015
Is this the right normalization? A diagnostic tool for ChIP-seq normalizationClaudia Angelini, Ruth Heller, Rita Volkinshtein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosisGiancarlo Comi, Yuval Dadon, Nissim Sasson, et al.
The Lancet. Neurology|January 27, 2024
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyRalf Reilmann, Karen E Anderson, Andrew Feigin, et al.
Pageof 1